

## CLAIMS

1. (currently amended) A composition including an effective amount of the polypeptide EEIIMD in the range of 2  $\mu$ M to 10  $\mu$ M, and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity ~~without causing cranial hemorrhage in a subject suffering from ischemic stroke, acute myocardial infarction, pulmonary emboli, peripheral artery disease or deep vein thrombosis.~~
2. (original) The composition according to claim 1, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
3. (cancelled)
4. (cancelled)
5. (cancelled)
6. (cancelled)
7. (currently amended) A method of enhancing the fibrinolytic activity of a fibrinolytic agent, said method comprising administering in vitro an effective amount of the polypeptide EEIIMD in the range of 2  $\mu$ M to 10  $\mu$ M, to enhance the activity and a suitable amount of a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity ~~without causing cranial hemorrhage in a subject suffering from ischemic stroke, acute myocardial infarction, pulmonary emboli, peripheral artery disease or deep vein thrombosis.~~

8. (original) The method according to claim 7, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolyated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
9. (cancelled).
10. (cancelled).